ATE533501T1 - Verwendung des ped-faktors zur induktion von zellregenerierung - Google Patents

Verwendung des ped-faktors zur induktion von zellregenerierung

Info

Publication number
ATE533501T1
ATE533501T1 AT07735311T AT07735311T ATE533501T1 AT E533501 T1 ATE533501 T1 AT E533501T1 AT 07735311 T AT07735311 T AT 07735311T AT 07735311 T AT07735311 T AT 07735311T AT E533501 T1 ATE533501 T1 AT E533501T1
Authority
AT
Austria
Prior art keywords
factor
induce cell
ped
regeneration
cell regeneration
Prior art date
Application number
AT07735311T
Other languages
English (en)
Inventor
Gamez Isabel Farinas
Agulla Celia Andreu
Ferran Sacramento Rodroeguez
Castillejo Carmen Ramoerez
Gamez Pilar Sanchez
Aparicio Helena Mira
Martoenez Julio Escribano
Sanchez Francisco Sanchez
Aguilar Jose Daniel Aroca
Original Assignee
Univ Valencia Estudi General
Univ Castilla La Mancha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Valencia Estudi General, Univ Castilla La Mancha filed Critical Univ Valencia Estudi General
Application granted granted Critical
Publication of ATE533501T1 publication Critical patent/ATE533501T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT07735311T 2006-02-17 2007-02-16 Verwendung des ped-faktors zur induktion von zellregenerierung ATE533501T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200600386A ES2329636B2 (es) 2006-02-17 2006-02-17 Uso del factor pedf para inducir la auto-renovacion de celulas madre.
PCT/IB2007/051115 WO2007093975A2 (es) 2006-02-17 2007-02-16 Uso del factor pedf para inducir la renovación de células

Publications (1)

Publication Number Publication Date
ATE533501T1 true ATE533501T1 (de) 2011-12-15

Family

ID=38371888

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07735311T ATE533501T1 (de) 2006-02-17 2007-02-16 Verwendung des ped-faktors zur induktion von zellregenerierung

Country Status (5)

Country Link
US (1) US20100047212A1 (de)
EP (1) EP2044952B1 (de)
AT (1) ATE533501T1 (de)
ES (1) ES2329636B2 (de)
WO (1) WO2007093975A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508196B1 (de) * 2011-03-23 2018-09-26 Mackay Memorial Hospital Verwendung von PEDF-abgeleiteten Polypeptiden zum Fördern der Stammzellenproliferation und Wundheilung
US9884012B2 (en) 2012-08-09 2018-02-06 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis
TWI491616B (zh) * 2012-08-09 2015-07-11 Mackay Memorial Hospital 色素上皮衍生因子衍生之多胜肽於促進肌肉或肌腱再生或動脈血管生成之用途
CN104903346B (zh) * 2012-09-19 2019-04-09 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 Pedf衍生的多肽在预防和/或缓和皮肤老化中的用途
US10724005B2 (en) 2012-09-28 2020-07-28 Scripps Health Methods of differentiating stem cells into chondrocytes
US10072247B2 (en) * 2012-10-05 2018-09-11 Samsung Life Public Welfare Foundation Composition comprising ischemic serum for promoting activation of stem cell and method for promoting activation of stem cell
EP2912166B1 (de) * 2012-10-29 2019-05-01 Scripps Health Verfahren zur herstellung von pluripotenten stammzellen aus chondrozyten
JP6324395B2 (ja) 2012-10-29 2018-05-16 スクリップス ヘルス 軟骨細胞を移植する方法
JP2017165745A (ja) * 2017-04-19 2017-09-21 マクカイ メモリアル ホスピタル 筋肉若しくは腱再生又は動脈形成を促進するためのｐｅｄｆ由来のポリペプチドの使用
JP7481261B2 (ja) * 2018-04-08 2024-05-10 ブリム バイオテクノロジー インク 腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US20040234505A1 (en) 1998-09-23 2004-11-25 Stuart Naylor Polynucleotide constructs and uses thereof
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US20010049369A1 (en) 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
JP2004516001A (ja) * 2000-02-23 2004-06-03 ノースウエスタン・ユニバーシテイ 新脈管形成を阻害するための方法および組成物
AU2001292881A1 (en) 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US20030082183A1 (en) 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
WO2002058730A2 (en) 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
DE10108412B4 (de) 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
SI1496944T1 (sl) 2002-05-01 2009-02-28 Univ Florida Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
AU2003287008A1 (en) 2002-09-19 2004-04-08 Tanox, Inc. Nuclear factor of activated t cells receptor
AU2003275259A1 (en) * 2002-09-26 2004-04-19 Northwestern University Anti-angiogenic fragments of pigment epithelium-derived factor (pedf)
US20060251621A1 (en) 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy
KR100875112B1 (ko) * 2002-11-16 2008-12-22 삼성에스디아이 주식회사 비수계 전해액 및 이를 채용한 리튬 전지
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
EP1684692A2 (de) * 2003-10-29 2006-08-02 The Johns Hopkins University Pigment-epithel-faktor, neue biologische wirkung und anwendungsverfahren
US20050222031A1 (en) 2004-03-19 2005-10-06 Yamagishi Sho-Ichi Method for preventing or treating malignant melanoma

Also Published As

Publication number Publication date
ES2329636B2 (es) 2010-07-26
EP2044952B1 (de) 2011-11-16
WO2007093975A3 (es) 2008-05-02
ES2329636A1 (es) 2009-11-27
EP2044952A2 (de) 2009-04-08
US20100047212A1 (en) 2010-02-25
WO2007093975A2 (es) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE533501T1 (de) Verwendung des ped-faktors zur induktion von zellregenerierung
CL2007003326A1 (es) Compuestos derivados de pirrol[2,3-b]piridina, moduladores de la actividad del c-fms y/o el c-kit; composicion farmaceutica; y uso para el tratamiento de tumores de celulas mamarias, asma, artritis reumatoide, enfermedad de parkinson, entre otras.
ECSP099332A (es) Moléculas de enlace de lingo y uso farmacéutico de las mismas
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
DOP2009000134A (es) Compuestos bicíclicos y su uso como anti-diabéticos
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2010001159A1 (es) Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros.
TW200612892A (en) Novel compounds
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
PT1730146E (pt) Azaindoles úteis como inibidores de jak e outras proteínas quinases
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
BRPI0511479C1 (pt) molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
MX2009002816A (es) Proteinas de fusion de albumina.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение